Canaccord Genuity Downgrades MAP Pharmaceuticals (MAPP) to Hold

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/13/2026

1. CSCO
2. CBRS
3. COHR
4. WYFI
5. STUB
6. CRS
7. EAT
8. GO
9. HLIT
10. ABN:NA

Go back to Canaccord Genuity Downgrades MAP Pharmaceuticals (MAPP) to Hold

Deutsche Bank Downgrades MAP Pharmaceuticals (MAPP) to Hold; Doesn't Expect Other Bids

January 28, 2013 9:02 AM EST

Deutsche Bank downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Buy to Hold following takeover deal. The firm doesn't expect other bids.

For an analyst ratings summary and ratings history on MAP Pharmaceuticals click here. For... More

Leerink Swann Downgrades MAP Pharmaceuticals (MAPP) to Market Perform

January 24, 2013 6:54 AM EST

Leerink Swann downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Outperform to Market Perform with a price target of $25.00 (from $19.00) following yesterday's takeover deal.

"We believe MAPP's $25/share takeout valuation is fair and includes some of the technology value in MAPP's Tempo inhaler device... More

Allergan (AGN) Acquires MAP Pharmaceuticals (MAPP) for $958M

January 23, 2013 6:34 AM EST

Allergan, Inc. (NYSE: AGN) agreed to acquire MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) for $25 per share, or approximately $958 million. The offer represents a 60% premium over MAPs closing stock price on the Nasdaq Stock Market of $15.58 on January 22, 2013.

The acquisition is expected to close late in the first quarter or in the second quarter of 2013.

In January 2011, Allergan entered into... More